A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-06

Study Completion Date

2025-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465

Sickle Cell Disease

COMPLETED PHASE2

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

NCT01565616

Sickle Cell Disease

COMPLETED PHASE2

Reduced Intensity Transplantation for Severe Sickle Cell Disease

NCT04362293

Sickle Cell Disease

SUSPENDED PHASE2

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

NCT01306019

X-linked Severe Combined Immunodeficiency (XSCID)

RECRUITING PHASE1/PHASE2

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

NCT06462365

Hematologic Malignancy GvHD GVHD,Acute +8 more

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subject participation in this study will be approximately 136 weeks. Enrolled subjects will be asked to participate in a separate long-term follow-up study to monitor the safety and efficacy of BIVV003 treatment for a total of 15 years post-transplant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BIVV003

Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.

Group Type EXPERIMENTAL

Plerixafor

Intervention Type BIOLOGICAL

Plerixafor subcutaneous injection will be administered prior to apheresis.

Busulfan

Intervention Type DRUG

Busulfan IV infusion will be administered as myeloablative conditioning therapy.

BIVV003

Intervention Type GENETIC

BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plerixafor

Plerixafor subcutaneous injection will be administered prior to apheresis.

Intervention Type BIOLOGICAL

Busulfan

Busulfan IV infusion will be administered as myeloablative conditioning therapy.

Intervention Type DRUG

BIVV003

BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.

Intervention Type GENETIC

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Autologous CD34 + hematopoietic stem cells

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18 to 40
* Confirmation of sickle cell disease (SCD) diagnosis (HbSS or HbS\[beta\]0 genotype)
* Severe SCD, defined as having 1 or more of the following manifestations: Clinically significant neurologic event (example \[e.g.\], stroke) or any neurological deficit lasting more than 24 hours; History of 2 or more episodes or Acute Chest Syndrome (ACS) in 2 years prior to informed consent (despite adequate supportive therapies such as asthma therapy); Six or more pain crises per year in 2 years prior to informed consent (requiring intravenous \[IV\] pain management in the outpatient or inpatient hospital setting); History of 2 or more cases or priapism with participant seeking medical care in the 2-years prior to informed consent; Regular RBC transfusion therapy in the year prior to informed consent (having received 8 or more transfusions to prevent vaso-occlusive clinical complications); and Echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity of greater than or equal to 2.5 meter per second (m/s)
* Clinically stable to undergo stem cell mobilization and myeloablative hematopoietic stem cell transplantation (HSCT)
* Adequate physiological function, defined as the following: Karnofsky/Lansky Performance of greater than or equal to 60; Acceptable cardiac function as defined in protocol; Acceptable pulmonary function as defined in protocol; Acceptable renal function as defined in protocol; and Acceptable hepatic function as defined in protocol
* Ability to understand purpose and risks of study, provide Informed Consent Form (ICF) and authorization to use protected health information
* Completion of age-appropriate cancer screening
* Willingness to use double-barrier method of contraception through entire study period (for participants of childbearing potential)
* Willingness to receive blood transfusions
* Willingness to discontinue hydroxyurea (HU) at least 30 days prior to stem cell mobilization through Day 100 post-transplantation

Exclusion Criteria

* Previous receipt of an autologous or allogeneic HSCT or solid organ transplantation
* Previous treatment with gene therapy
* Current enrollment in an interventional study or having received an investigational drug within 30 days of study enrollment
* Pregnant or breastfeeding female
* Female or male who plans to become pregnant or impregnate a partner, respectively, during the anticipated study period
* Contraindication to plerixafor, apheresis, or busulfan
* Treatment with prohibited medication in previous 30 days
* Known allergy or hypersensitivity to plerixafor, busulfan, or investigational product excipients
* History of active malignancy within past 5 years, any history of hematologic malignancy, or a family history of a cancer predisposition syndrome (without negative result of candidate)
* Current diagnosis of uncontrolled seizures
* History of significant bleeding disorder
* Clinically significant infection
* Any major organ dysfunction involving brain, kidney, liver, lung, or heart (e.g., congestive heart failure, pulmonary hypertension)
* Corrected QT interval of more than 500 millisecond (ms) based on screening electrocardiogram (ECG)
* Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
* Known to have a gamma-globin variant associated with altered oxygen affinity
* Hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration of more than or equal to 20 percent (%) at screening
* Absolute Neutrophil Count (ANC) of less than or equal to 1,000 per microliter
* Platelet count of less than 100,000 per microliter
* History of platelet alloimmunization (precluding ability to provide transfusion support)
* Extensive Red Blood Cell (RBC) alloimmunization (precluding ability to provide transfusion support)
* Judged unsuitable for participation by investigator and/or sponsor

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No